WO2007100525A3 - Traitement antiviral - Google Patents

Traitement antiviral Download PDF

Info

Publication number
WO2007100525A3
WO2007100525A3 PCT/US2007/004168 US2007004168W WO2007100525A3 WO 2007100525 A3 WO2007100525 A3 WO 2007100525A3 US 2007004168 W US2007004168 W US 2007004168W WO 2007100525 A3 WO2007100525 A3 WO 2007100525A3
Authority
WO
WIPO (PCT)
Prior art keywords
encephalitis
group
ingredient selected
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004168
Other languages
English (en)
Other versions
WO2007100525A2 (fr
Inventor
Ruben G Fabunan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fil-Am Tech Inc
FIL AM TECH Inc
Original Assignee
Fil-Am Tech Inc
FIL AM TECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fil-Am Tech Inc, FIL AM TECH Inc filed Critical Fil-Am Tech Inc
Publication of WO2007100525A2 publication Critical patent/WO2007100525A2/fr
Publication of WO2007100525A3 publication Critical patent/WO2007100525A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les maladies à virus du SRAS, Ebola, de Marburg, du Nil occidental, de la rubéole, de la fièvre jaune, de l'encéphalite américaine de Saint-Louis, de l'encéphalite japonaise, de l'encéphalite de Californie, de la leucémie humaine des lymphocytes T, de la maladie de Newcastle, des infections du système respiratoire et de la bronchite, de la maladie d'Armstrong, de la fièvre hémorragique de Lassa et de la fièvre hémorragique de Hantaan sont traitées par une injection intramusculaire d'un mélange comprenant un premier constituant choisi dans le groupe constitué par la procaïne, la chloroprocaïne, la tétracaïne, la chlorotétracaïne, la bromoprocaïne, la proparacaïne, la fluoroprocaïne et la benzocaïne, et un deuxième constituant choisi dans le groupe constitué par la dexaméthasone, la fluméthasone et la bétaméthasone.
PCT/US2007/004168 2006-02-27 2007-02-15 Traitement antiviral Ceased WO2007100525A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77705206P 2006-02-27 2006-02-27
US60/777,052 2006-02-27

Publications (2)

Publication Number Publication Date
WO2007100525A2 WO2007100525A2 (fr) 2007-09-07
WO2007100525A3 true WO2007100525A3 (fr) 2008-07-31

Family

ID=38459508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004168 Ceased WO2007100525A2 (fr) 2006-02-27 2007-02-15 Traitement antiviral

Country Status (1)

Country Link
WO (1) WO2007100525A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014000275A1 (en) * 2014-09-30 2016-08-31 Fabunan M D Ruben Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids
AU2021245379A1 (en) * 2020-04-02 2022-11-10 Inflamed Pharma Gmbh Active substances for medical use
CN115697318A (zh) * 2020-04-02 2023-02-03 炎症药物有限责任公司 医用活性物质
LU101724B1 (de) * 2020-04-02 2021-10-04 Inflamed Pharma Gmbh Wirkstoffe zur medizinischen Verwendung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492901A (en) * 1994-08-16 1996-02-20 Fabunan; Ruben G. Cobranin-F injection envenomation antidote
US6172053B1 (en) * 1999-02-24 2001-01-09 Ruben G. Fabunan Injection viral treatment
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492901A (en) * 1994-08-16 1996-02-20 Fabunan; Ruben G. Cobranin-F injection envenomation antidote
US6172053B1 (en) * 1999-02-24 2001-01-09 Ruben G. Fabunan Injection viral treatment
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUCHS ET AL.: "Inhibition of adsorption of West-Nile and Herpes Simplex viruses by procaine", ARCHIVES OF VIROLOGY, vol. 56, 1978, pages 13 - 168 *

Also Published As

Publication number Publication date
WO2007100525A2 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007111866A3 (fr) Combinaisons d'un ou plusieurs inhibiteurs de la protéase du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et méthodes de traitement associées
CA2633594C (fr) Moyens et procedes pour le traitement de maladies tumorales
WO2006031398A3 (fr) Compositions renfermant des plastifiants a lixiviation rapide et permettant d'ameliorer les performances de dispositifs medicaux
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
WO2008024843A3 (fr) Méthode de thérapie combinatoire pour le traitement d'une infection par le virus de l'hépatite c et compositions pharmaceutiques correspondantes
WO2007100525A3 (fr) Traitement antiviral
MX2009011512A (es) Nuevos compuestos peptidos ciclicos.
WO2004110349A3 (fr) Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes
WO2003097050A3 (fr) Methodes de traitement de maladies et de troubles respiratoires avec un inhibiteur inos selectif et un inhibiteur pde et compositions a cet effet
WO2005107753A3 (fr) Procede et systeme d'investigation anonyme etendue basee sur des faits et d'etablissement de rapports a base de faits et d'acces selectif aux resultats et rapports
WO2006058202A3 (fr) Agents diagnostiques et therapeutiques a base de mer
WO2005051331A3 (fr) Traitement a base de chaperone destine a la maladie de niemann-pick
WO2005112915A3 (fr) Diminution de l'etat de stress oxydatif par administration de produits naturels et de medicaments pharmaceutiques
WO2007030944A3 (fr) Methodes de cardioprotection consistant a utiliser du dichloroacetate combine a un inotrope
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2006048452A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
EP2071030A3 (fr) Oligoribonucléotide ou acide nucléique de peptide qui inhibe l'action du virus de l'hépatite C
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2005023270A3 (fr) Compositions et methodes d'utilisation de medicaments antiviraux dans le traitement de maladies retrovirales resistantes aux inhibiteurs nucleosidiques de la transcriptase inverse
WO2003097163A3 (fr) Methodes de traitement de maladies et troubles respiratoires au moyen d'un inhibiteur selectif de l'inos
WO2006133194A3 (fr) Methodes permettant de traiter une infection virale a l'aide d'une solution medicamenteuse orale ou injectable
WO2007092607A3 (fr) Traitement d'infections virales hémorragiques au moyen d'un inhibiteur du facteur tissulaire
WO2007057436A3 (fr) L’interferon dans la grippe
WO2009090240A3 (fr) Utilisation du facteur viia ou d'équivalents du facteur viia pour prévenir ou atténuer une évolution hémorragique et/ou la génération d'un œdème à la suite d'une hémorragie intracérébrale (ich) chez une sous-population sélectionnée de patients ich
WO2007059356A3 (fr) Inhibiteurs de l'ubiquitine e1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07750966

Country of ref document: EP

Kind code of ref document: A2